- Home
- HROW vs DFIN Comparison
HROW vs DFIN Comparison
Compare HROW & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- DFIN
- Stock Information
- Founded
- HROW 1998
- DFIN 1983
- Country
- HROW United States
- DFIN United States
- Employees
- HROW N/A
- DFIN N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- DFIN Other Consumer Services
- Sector
- HROW Health Care
- DFIN Consumer Discretionary
- Exchange
- HROW Nasdaq
- DFIN Nasdaq
- Market Cap
- HROW 1.4B
- DFIN 1.4B
- IPO Year
- HROW N/A
- DFIN N/A
- Fundamental
- Price
- HROW $39.74
- DFIN $53.33
- Analyst Decision
- HROW Strong Buy
- DFIN Strong Buy
- Analyst Count
- HROW 7
- DFIN 3
- Target Price
- HROW $68.50
- DFIN $68.67
- AVG Volume (30 Days)
- HROW 889.7K
- DFIN 283.1K
- Earning Date
- HROW 11-12-2025
- DFIN 10-30-2025
- Dividend Yield
- HROW N/A
- DFIN N/A
- EPS Growth
- HROW N/A
- DFIN N/A
- EPS
- HROW N/A
- DFIN 2.79
- Revenue
- HROW $227,661,000.00
- DFIN $755,000,000.00
- Revenue This Year
- HROW $43.92
- DFIN N/A
- Revenue Next Year
- HROW $41.32
- DFIN $4.66
- P/E Ratio
- HROW N/A
- DFIN $19.22
- Revenue Growth
- HROW 47.69
- DFIN N/A
- 52 Week Low
- HROW $20.85
- DFIN $37.80
- 52 Week High
- HROW $59.23
- DFIN $69.93
- Technical
- Relative Strength Index (RSI)
- HROW 45.21
- DFIN N/A
- Support Level
- HROW $40.79
- DFIN N/A
- Resistance Level
- HROW $48.79
- DFIN N/A
- Average True Range (ATR)
- HROW 2.41
- DFIN 0.00
- MACD
- HROW -0.87
- DFIN 0.00
- Stochastic Oscillator
- HROW 11.18
- DFIN 0.00
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.